Patents by Inventor Susan Barnett

Susan Barnett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180360949
    Abstract: The invention provides, inter alia, compositions useful for, e.g., raising an immune response to HIV-1, and associated methods of raising an immune response to HIV in a mammalian subject. In some embodiments, the compositions are bivalent immunogenic compositions comprising two (or, in some embodiments more than two) human immunodeficiency virus (HIV) clade C envelope gp120 polypeptide antigens, together with a liposome-based adjuvant, such as the adjuvant known as AS01.
    Type: Application
    Filed: December 16, 2016
    Publication date: December 20, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Susan BARNETT, Marguerite Christine KOUTSOUKOS, Clarisse Marie-Madeleine LORIN, Frederick PORTER, Zihao WANG, Ying ZHANG
  • Patent number: 9598469
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: March 21, 2017
    Assignees: Novartis Vaccines and Diagnostics, Inc., University of Stellenbosch
    Inventors: Jan Zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse Van Rensberg, Thomas J. Scriba
  • Publication number: 20150140068
    Abstract: This invention generally relates to immunogenic compositions that comprise an HIV RNA component and a HIV polypeptide component. Immunogenic compositions that deliver antigenic epitopes in two different forms—a first epitope from human immunodeficiency virus (HIV), in RNA-coded form; and a second epitope from HIV, in polypeptide form—are effective in inducing immune response to HIV. The invention also relates to a kit comprising an HIV RNA-based priming composition and an HIV polypeptide-based boosting composition. The kit may be used for sequential administration of the priming and the boosting compositions.
    Type: Application
    Filed: June 29, 2013
    Publication date: May 21, 2015
    Inventors: Susan Barnett, Kaustuv Bannerjee, Gillis Otten, Andrew Geall
  • Publication number: 20140242152
    Abstract: This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigenic epitopes in two different forms—a first epitope from a pathogen, in RNA-coded form; and a second epitope from the same pathogen, in polypeptide form—are effective in inducing immune response to the pathogen. The invention also relates to a kit comprising an RNA-based priming composition and a polypeptide-based boosting composition. The kit may be used for sequential administration of the priming and the boosting compositions.
    Type: Application
    Filed: July 6, 2012
    Publication date: August 28, 2014
    Inventors: Andrew Geall, Gillis Otten, Susan Barnett
  • Publication number: 20140220060
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Application
    Filed: December 26, 2013
    Publication date: August 7, 2014
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Jan ZUR MEGEDE, Susan BARNETT, Ying LIAN, Susan ENGELBRECHT, Estrelita Janse VAN RENSBERG, Thomas J. SCRIBA
  • Patent number: 8647864
    Abstract: Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems and Alphavirus replicon particles for introducing heterologous sequences into cells for generating immune responses.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: February 11, 2014
    Assignee: Novartis AG
    Inventors: John M Polo, Thomas W Dubensky, Jr., Ilya Frolov, Jason P Gardner, Gillis Otten, Susan Barnett, David A Driver
  • Patent number: 8637044
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: January 28, 2014
    Assignee: Novartis AG
    Inventors: Susan Barnett, Rino Rappuoli, Victoria A Sharma, Indresh K Srivastava, Jan Zur Megede
  • Publication number: 20120276128
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Methods of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Application
    Filed: July 9, 2012
    Publication date: November 1, 2012
    Inventors: Susan Barnett, Indresh Srivastava
  • Publication number: 20120269851
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof.
    Type: Application
    Filed: February 17, 2012
    Publication date: October 25, 2012
    Applicants: University of Stellenbosch, NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg, Thomas J. Scriba
  • Publication number: 20120183557
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 19, 2012
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS. INC.
    Inventors: Susan BARNETT, Rino RAPPUOLI, Victoria A. SHARMA, Indresh K. SRIVASTAVA, Jan ZUR MEGEDE
  • Patent number: 8168194
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Grant
    Filed: February 3, 2006
    Date of Patent: May 1, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Susan Barnett, Rino Rappuoli, Victoria A. Sharma, Indresh K. Srivastava, Jan Zur Megede
  • Patent number: 8133494
    Abstract: The invention relates to polynucleotides encoding modified immunogenic HIV-1 South African subtype C Env polypeptides. The modifications to the Env polypeptides include deletions of V1, V2 and the stem region. The expression cassettes may be used, for example, to express the encoded polypeptide. A recombinant expression system for use in a selected host cell comprising an expression cassette encoding for the modified HIV-1 Env polypeptide is also described.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: March 13, 2012
    Assignee: Novartis Vaccine & Diagnostics Inc
    Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse van Rensburg, Thomas J. Scriba
  • Publication number: 20110212164
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C Pol, Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Pol, Gag- and/or Env-containing proteins are also described.
    Type: Application
    Filed: May 2, 2011
    Publication date: September 1, 2011
    Applicant: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Susan BARNETT, Jan Zur Megede
  • Patent number: 7935805
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C Pol, Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Pol, Gag- and/or Env-containing proteins are also described.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: May 3, 2011
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan Barnett, Jan Zur Megede
  • Publication number: 20110020396
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Method of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Application
    Filed: August 19, 2010
    Publication date: January 27, 2011
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Susan Barnett, Indresh Srivastava
  • Publication number: 20100316698
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described.
    Type: Application
    Filed: November 17, 2009
    Publication date: December 16, 2010
    Applicants: Novartis Vaccines and Diagnostics, Inc., University of Stellenbosch
    Inventors: Jan zur Megede, Susan Barnett, Ying Lian, Susan Engelbrecht, Estrelita Janse Van Rensburg
  • Publication number: 20100285062
    Abstract: HIV antigens are mucosally administered in one or more priming immunization(s), and then HIV antigens are parenterally administered in one or more boosting immunization(s). Thus the invention provides a method for raising an immune response in a patient, comprising: (i) administering a HIV antigen to the patient via a mucosal route; and then (ii) administering a HIV antigen to the patient via a parenteral route. The antigens will typically be adjuvanted. Preferred mucosal immunizations are via the intranasal route using a detoxified mutant of E. coli heat labile toxin as the adjuvant. Preferred parenteral immunizations are via the intramuscular route using an oil-in-water emulsion adjuvant.
    Type: Application
    Filed: March 29, 2007
    Publication date: November 11, 2010
    Applicant: NOVARTIS AG
    Inventors: Rino Rappuoli, David L.M. Lewis, Susan Barnett
  • Publication number: 20100266631
    Abstract: Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems and Alphavirus replicon particles for introducing heterologous sequences into cells for generating immune responses.
    Type: Application
    Filed: June 29, 2010
    Publication date: October 21, 2010
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: John Polo, Thomas W. Dubensky, JR., Ilya Frolov, Jason P. Gardner, Gillis Otten, Susan Barnett, David A. Driver
  • Patent number: 7811580
    Abstract: Env-CD4 complexes and hybrids are disclosed that expose cryptic epitopes that are important in virus neutralization. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: May 7, 2003
    Date of Patent: October 12, 2010
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Susan Barnett, Indresh Srivastava
  • Patent number: 7771979
    Abstract: Methods are provided for generating immune responses utilizing alphavirus-based vector systems.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: August 10, 2010
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: John Polo, Thomas W. Dubensky, Jr., Ilya Frolov, Jason P. Gardner, Gillis Otten, Susan Barnett, David A. Driver